NCT06100276
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
At risk: Primary completion moved 4 years 3 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 14 versions: 14 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Sep 30, 2026 to Dec 30, 2030
- Eligibility criteria expanded, about 12 words
- Study completion pushed from Jun 30, 2031 to Nov 30, 2031
- Secondary endpoints: details revised at 2 of 2 entries
- Minor Trial status: Recruiting to Active, Not Recruiting
- Study sites: 10 to 12
- Study completion date: Mar 30, 2031 to Jun 30, 2031
- Minor Site details revised at 10 of 10 sitesv12
- Minor Site details revised at 3 of 10 sitesv11
- Notable Eligibility criteria expanded, about 36 words
- Study sites: 6 to 10
Show 8 earlier versionsHide 8 earlier versions
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Jul 30, 2024 to Aug 1, 2024
- Site details revised at 6 of 6 sites
- Minor Study arms: 1 to 2v8
- Minor Study arms: 2 to 1v7
Notable Enrollment target: 12 to 20v6 Show 4 more changesShow less
- Start date: May 30, 2024 to Jul 30, 2024
- Eligibility criteria expanded, about 9 words
- Study sites revised (6)
- Study arms: 1 to 2
- Minor Study sites: 4 to 6v5
Notable Enrollment target: 42 to 12v4 Show 10 more changesShow less
- Start date: Feb 1, 2024 to May 30, 2024
- Eligibility criteria shortened, about 517 words
- Primary endpoints: 3 to 1
- Study sites: 0 to 4
- Primary completion date: Jun 30, 2026 to Sep 30, 2026
- Study completion date: Feb 27, 2032 to Mar 30, 2031
- Secondary endpoints revised (2)
- Study description revised
- Study arms: 3 to 1
- Study title expanded, about 1 word
- Notable Start date: Nov 1, 2023 to Feb 1, 2024v3
- Notable Eligibility criteria expanded, about 5 words
- Secondary endpoints: details revised at 2 of 2 entries
- Study title expanded, about 3 words
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (2)
Arms and interventions
Experimental: 3 single Ascending Dose Levels The study will be open-label with an initial plan to explore 3 dose levels of AMT-162 in approximately 6 to 12 Participants in total. Each Participant will receive a single dose of AMT-162 delivered via an intrathecal (IT) infusion and will be followed for up to 5 years after AMT-162 administration.
Expansion cohort: To further test selected dose from the SAD part in approximately 6 to 8 participants The study will be open-label. Each Participant will receive a single dose of AMT-162 delivered via an intrathecal (IT) infusion and will be followed for up to 5 years after AMT-162 administration.
Drugs: AMT-162
Sites
12 sites in 2 countries
United States 11, Sweden 1